MHRA Class 2 Medicines Recall: Irbesartan & Losartan containing products : PSNC
With more money than ever flowing through biopharma, the massive demand for scalable manufacturing has created a big crunch on finding and training a stable workforce. With the work never stopping, some companies are desperately trying to figure out how to attract more qualified employees.
Bristol Myers Squibb has made a big push in recent years to take its anti-PD(L)1 Opdivo — both solo and in combination with Yervoy — into gastric cancer across a range of treatment settings. The drugmaker scored a big approval in adjuvant patients with one form of the disease in May, and now it’s turning out mostly positive late-stage data for another indication.
Another oral multiple sclerosis drug is here, challenging a slate of existing players that includes heavyweights Novartis, Bristol Myers Squibb, Sanofi and Biogen.
Locked in a heated battle for I/O supremacy, Merck and Bristol have readily engaged in proxy battles for new indications, tag-teaming their blockbusters with other meds to get a leg up. Now, after already scoring a combo win with another TKI inhibitor in kidney cancer, Merck is holding up promising data for another Keytruda pairing.
When Bristol Myers Squibb and Exelixis first unveiled kidney cancer data for the combination of Opdivo and Cabometyx last fall, industry watchers couldn’t determine a clear winner between that duo and Merck & Co. and Pfizer’s Keytruda-Inlyta cocktail. Now, with longer-term data, the jury’s still out.
Bristol Myers Squibb (BMS) announced on Feb. 5, 2021 that FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel), BMS’ chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
When Bristol Myers Squibb picked up Celgene in its massive 2019 buyout, a key question lingering over the deal was the timing around Revlimid generics. They're now a little more than a year away thanks to a patent settlement, and Bristol execs are busy detailing how the company will continue to grow through the megablockbuster’s decline.
Amylyx taps Frates as CFO. BMS hematology chief hits exit. Moderna names Le Goff chief commercial officer.
For existing PD-1/L1 inhibitors, China represents an opportunity for new growth. But foreign drugmakers have once again lost their chance to reach a wider pool of patients in the country as local players make inroads by offering steep discounts.